Brief: Kinnate Biopharma Inc. Adds Two New Drug Candidates To Its Growing Targeted Oncology Pipeline And Provides Cash Runway Guidance

Kinnate Biopharma

17/04/2023 19:57

April 17 (Reuters) - Kinnate Biopharma Inc  KNTE.O :
    * KINNATE BIOPHARMA INC. ADDS TWO NEW DRUG CANDIDATES TO ITS
GROWING TARGETED ONCOLOGY PIPELINE AND PROVIDES CASH RUNWAY
GUIDANCE
    * KINNATE BIOPHARMA - ABOUT $231 MILLION OF CASH, CASH
EQUIVALENTS
AND INVESTMENTS AS OF MARCH 31, 2023 IS ANTICIPATED TO FUND
PLANNED OPERATIONS INTO EARLY 2025 
    * KINNATE BIOPHARMA INC - KINNATE TO EVALUATE STRATEGIC
ALTERNATIVES FOR ITS CDK12 PROGRAM
    * KINNATE BIOPHARMA INC - ABOUT $231 MILLION OF CASH, CASH
EQUIVALENTS AND INVESTMENTS AS OF MARCH 31, 2023
    * KINNATE BIOPHARMA INC - KIN-7136 IS EXPECTED TO ENTER
CLINIC IN
H2 OF 2023
    * KINNATE BIOPHARMA INC - EXPECTS TO ENTER CLINIC WITH
KIN-8741 IN
FIRST HALF OF 2024, PENDING FDA CLEARANCE ON ITS IND APPLICATION
    * KINNATE BIOPHARMA INC - WILL DEPRIORITIZE DEVELOPMENT FOR
ITS
CDK12 PROGRAM

Source text for Eikon:  ID: 

 ((Reuters.Briefs@thomsonreuters.com;))